ClinicalTrials.gg
RecruitingNCT07314723Updated Jan 2, 2026

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

A Phase 2 interventional study of 9MW2821 and Toripalimab Injection in Urothelial Carcinoma, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Aug 2025, registered Dec 2025).
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Carcinoma, Transitional Cell with a site in China — 51 open to participants now, 56 under way, 9 of them phase 3. Carcinoma, Transitional Cell · China.

Planned enrollment
29th of 69
90 · median 60
Started
2025
with 12 others
Phase 2
30 of 88
18 open now
Primary completion
2027-12
later than 39 of 55 live
Registered
68th of 88
by date
Lead sponsor
3 of 88
Mabwell (Shanghai) Bioscience Co., Ltd.

Among the 88 studies in Carcinoma, Transitional Cell with a site in China, this one is the 29th largest by planned enrollment of the 69 interventional ones that give a count, is one of 13 that started in 2025, is one of 30 in phase 2, reaches primary completion later than 39 of the 55 other live ones, and was the 68th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

51 of the 88 studies in Carcinoma, Transitional Cell with a site in China are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Carcinoma, Transitional Cell with a site in China, or all of them as a file.
02

Study summary

This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.

03

Conditions studied

  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the form approved by IEC.
  • Male or female subjects aged ≥18 years old.
  • status: 0 or 1.
  • confirmed urothelial cancer.
  • Imaging confirmed non- urothelial cancer (M0). Arm 1: MIBC, T2-4aN0-1. Arm 2: High-risk UTUC, N0. Arm 3: MIBC, T2-4aN0.
  • Adequate tumor tissues submitted for test.
  • for more than 12 weeks.
  • Adequate organ functions.
  • Proper methods.
  • Willingness to follow the study procedures.

Exclusion criteria

Exclusion Criteria:

  • Prior systemic anti-tumor therapy for urothelial cancer.
  • Previously treated with /PD-L1 inhibitors or antibody-drug conjugates (ADCs).
  • History of another within 3 years.
  • History of disease requiring systemic treatment within 2 years.
  • History of cardiac/cerebrovascular diseases or thrombosis within 1 year.
  • Major surgery treated within 28 days; Cystoscopy/ureteroscopy or intravesical instillation therapy within 7 days.
  • Peripheral neuropathy Grade ≥ 2.
  • Any situations adding the risk of severe dry eye, active keratitis or corneal ulcer, etc.
  • Active // infection, etc.
  • Any other serious chronic or uncontrolled disease.
  • Any got within 28 days.
  • Organ transplantation or hematopoietic stem cell transplantation in the past.
  • Any potent inducers/inhibitors taken within 14 days.
  • Known allergic sensitivity to any of the ingredients of the study drug.
  • History of drug abuse or mental illness.
  • Other conditions unsuitable into the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Arm 1: MIBC

    Drug: 9MW2821 · Drug: Toripalimab Injection

  • Experimental
    Arm 2: High-risk UTUC

    Drug: 9MW2821 · Drug: Toripalimab Injection

  • Experimental
    Arm 3: MIBC

    Drug: 9MW2821 · Drug: Toripalimab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. pCR (Arm 1 and 2)

    Pathological complete response

    Time frame: Up to 24 months

  2. cCR (Arm 3)

    Clinical complete response

    Time frame: Up to 24 months

Secondary outcomes

  1. cORR

    Clinical objective response rate

    Time frame: Up to 24 months

  2. Pathological downstaging rate (Arm 1 and 2)

    Time frame: Up to 24 months

  3. DFS (Arm 1 and 2)

    Disease-free survival

    Time frame: Up to 24 months

  4. Duration of clinical complete response (Arm 3)

    Time frame: Up to 24 months

  5. PFS (Arm 3)

    Progression-free survival

    Time frame: Up to 24 months

  6. OS

    Overall Survival

    Time frame: Up to 24 months

  7. AE/SAE

    Adverse event, serious adverse event

    Time frame: Up to 24 months

  8. Immunogenicity

    Anti-Drug Antibody (ADA) of 9MW2821

    Time frame: Up to 24 months

  9. Nectin-4 and PD-L1 expression

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.

Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2025
First posted
Jan 2, 2026
StartActual
Aug 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07314723
Responsible party
Sponsor
First posted
Jan 2, 2026
Start date
Aug 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jan 2, 2026

Study contacts

Zhuowei Liu, Professor
Contact
liuzhw@sysucc.org.cn
86-20-87343606

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulumtatug fuvedotin

Start the discussion